NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
March 12, 2020 17:00 ET
|
NextCure
BELTSVILLE, Md., March 12, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at the 40th Annual Cowen Health Care Conference
February 25, 2020 08:05 ET
|
NextCure
BELTSVILLE, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference
February 18, 2020 08:05 ET
|
NextCure
BELTSVILLE, Md., Feb. 18, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 16:10 ET
|
NextCure
BELTSVILLE, Md., Jan. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference
November 26, 2019 08:05 ET
|
NextCure
BELTSVILLE, Md., Nov. 26, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Announces Closing of Public Offering
November 19, 2019 16:05 ET
|
NextCure
BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Announces Pricing of Public Offering of Common Stock
November 14, 2019 22:10 ET
|
NextCure
BELTSVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Announces Proposed Public Offering of Common Stock
November 12, 2019 16:18 ET
|
NextCure
BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Reports Third Quarter 2019 Financial Results
November 12, 2019 08:05 ET
|
NextCure
BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial
November 09, 2019 17:05 ET
|
NextCure
NC318 was well toleratedSingle agent activity observed in multiple tumor types, including a CR and a PR in NSCLCInitiated Phase 2 portion of the Phase 1/2 monotherapy trial and plans for a combo trial...